• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

接受奥氮平治疗的双相情感障碍患者体重显著增加的早期预测因素。

Early predictors of substantial weight gain in bipolar patients treated with olanzapine.

作者信息

Lipkovich Ilya, Citrome Leslie, Perlis Roy, Deberdt Walter, Houston John P, Ahl Jonna, Hardy Thomas

机构信息

Lilly Research Laboratories, Eli Lilly and Company, Lilly Corporate Center, Indianapolis, IN 46285, USA.

出版信息

J Clin Psychopharmacol. 2006 Jun;26(3):316-20. doi: 10.1097/01.jcp.0000219916.88810.1c.

DOI:10.1097/01.jcp.0000219916.88810.1c
PMID:16702898
Abstract

To determine predictors of substantial weight gain (SWG) during treatment of bipolar disorder with olanzapine, data were pooled from 4 long-term randomized, multicenter studies in patients with bipolar mania or mixed mania (N = 948 at initiation of olanzapine). SWG was defined as gaining 5 kg or 7% of initial weight in 30 +/- 2 weeks. Logistic regression estimated odds ratios associated with early weight gain and baseline risk factors for predicting SWG. A classification system to identify patients at risk for SWG was constructed by recursive data partitioning. Baseline characteristics significantly associated with SWG included younger age, nonwhite ethnicity, lower body mass index (BMI), nonrapid cycling, and psychotic features. Weight gain of 2 or more kg in the first 3 weeks of therapy predicted SWG by 30 weeks (sensitivity = 57%; specificity = 71%). A classification system with thresholds for early weight gain, baseline BMI, and ethnicity further improved SWG predictability (sensitivity = 79%; specificity = 70%). In conclusion, patients with bipolar disorder who gained 2 to 3 kg during the first 3 weeks of treatment with olanzapine, SWG was predicted after 30 weeks of treatment. Patients with less pronounced early weight gain might still be at risk for later SWG if they have close to normal BMI (< or =27 kg/m) at treatment initiation.

摘要

为了确定使用奥氮平治疗双相情感障碍期间显著体重增加(SWG)的预测因素,我们汇总了4项针对双相躁狂或混合性躁狂患者的长期随机多中心研究的数据(奥氮平治疗开始时N = 948)。SWG定义为在30±2周内体重增加5 kg或初始体重的7%。采用逻辑回归估计与早期体重增加相关的比值比以及预测SWG的基线危险因素。通过递归数据分割构建了一个识别SWG风险患者的分类系统。与SWG显著相关的基线特征包括年龄较小、非白人种族、较低的体重指数(BMI)、非快速循环发作以及精神病性特征。治疗前3周体重增加2 kg或更多可预测30周时的SWG(敏感性 = 57%;特异性 = 71%)。一个包含早期体重增加、基线BMI和种族阈值的分类系统进一步提高了SWG的预测性(敏感性 = 79%;特异性 = 70%)。总之,在使用奥氮平治疗的前3周体重增加2至3 kg的双相情感障碍患者,在治疗30周后可预测SWG。如果在治疗开始时BMI接近正常(≤27 kg/m²),早期体重增加不明显的患者后期仍可能有SWG风险。

相似文献

1
Early predictors of substantial weight gain in bipolar patients treated with olanzapine.接受奥氮平治疗的双相情感障碍患者体重显著增加的早期预测因素。
J Clin Psychopharmacol. 2006 Jun;26(3):316-20. doi: 10.1097/01.jcp.0000219916.88810.1c.
2
Early predictors of weight gain risk during treatment with olanzapine: analysis of pooled data from 58 clinical trials.奥氮平治疗期间体重增加风险的早期预测因素:来自58项临床试验的汇总数据分析
Psychopharmacol Bull. 2009;42(4):23-39.
3
Weight gain during treatment of bipolar I patients with olanzapine.使用奥氮平治疗双相I型患者期间的体重增加。
J Clin Psychiatry. 2004 Dec;65(12):1679-87. doi: 10.4088/jcp.v65n1214.
4
Lower weight gain with the orally disintegrating olanzapine than with standard tablets in first-episode never treated psychotic patients.首发未治疗的精神病患者口服奥氮平口崩片时的体重增加低于口服标准片剂时。
Hum Psychopharmacol. 2007 Jan;22(1):11-5. doi: 10.1002/hup.819.
5
Olanzapine versus lithium in the acute treatment of bipolar mania: a double-blind, randomized, controlled trial.奥氮平与锂盐治疗双相躁狂症急性期的疗效比较:一项双盲、随机、对照试验
J Affect Disord. 2008 Jan;105(1-3):101-8. doi: 10.1016/j.jad.2007.04.020. Epub 2007 May 24.
6
Melatonin for Reducing Weight Gain Following Administration of Atypical Antipsychotic Olanzapine for Adolescents with Bipolar Disorder: A Randomized, Double-Blind, Placebo-Controlled Trial.褪黑素用于减少双相情感障碍青少年使用非典型抗精神病药物奥氮平后的体重增加:一项随机、双盲、安慰剂对照试验
J Child Adolesc Psychopharmacol. 2017 Jun;27(5):440-444. doi: 10.1089/cap.2016.0046. Epub 2017 Mar 24.
7
Predictors of antipsychotic-induced weight gain in first-episode psychosis: conclusions from a randomized, double-blind, controlled prospective study of olanzapine, risperidone, and haloperidol.首发精神病患者抗精神病药物所致体重增加的预测因素:一项关于奥氮平、利培酮和氟哌啶醇的随机、双盲、对照前瞻性研究的结论
J Clin Psychopharmacol. 2008 Feb;28(1):27-31. doi: 10.1097/jcp.0b013e3181602fe6.
8
A randomized, placebo-controlled study of zonisamide to prevent olanzapine-associated weight gain.一项随机、安慰剂对照研究佐米曲普坦预防奥氮平相关体重增加。
J Clin Psychopharmacol. 2012 Apr;32(2):165-72. doi: 10.1097/JCP.0b013e3182488758.
9
The antidepressant effects of risperidone and olanzapine in bipolar disorder.利培酮和奥氮平在双相情感障碍中的抗抑郁作用。
Can J Clin Pharmacol. 2004 Fall;11(2):e218-26. Epub 2004 Oct 4.
10
Olanzapine versus placebo in the treatment of adolescents with bipolar mania.奥氮平与安慰剂治疗青少年双相躁狂症的对比研究
Am J Psychiatry. 2007 Oct;164(10):1547-56. doi: 10.1176/appi.ajp.2007.06111932.

引用本文的文献

1
Atypical antipsychotic use does not impact weight gain for individuals with extreme anorexia nervosa: a retrospective case-control study.非典型抗精神病药物的使用对患有极端神经性厌食症的个体的体重增加没有影响:一项回顾性病例对照研究。
J Eat Disord. 2023 Dec 6;11(1):215. doi: 10.1186/s40337-023-00941-6.
2
Compliance as a stable function in the treatment course of bipolar disorder in patients stabilized on olanzapine: results from a 24-month observational study.奥氮平稳定治疗双相情感障碍患者中依从性作为一项稳定功能:一项为期 24 个月的观察性研究结果。
Int J Bipolar Disord. 2014 Oct 23;2(1):13. doi: 10.1186/s40345-014-0013-x. eCollection 2014 Dec.
3
Olanzapine in Chinese patients with schizophrenia or bipolar disorder: a systematic literature review.
奥氮平用于中国精神分裂症或双相情感障碍患者:一项系统文献综述
Neuropsychiatr Dis Treat. 2014 May 16;10:841-64. doi: 10.2147/NDT.S58096. eCollection 2014.
4
Almost all antipsychotics result in weight gain: a meta-analysis.几乎所有抗精神病药物都会导致体重增加:一项荟萃分析。
PLoS One. 2014 Apr 24;9(4):e94112. doi: 10.1371/journal.pone.0094112. eCollection 2014.
5
A gender analysis of the study of pharmacotherapy of psychotic depression (STOP-PD): gender and age as predictors of response and treatment-associated changes in body mass index and metabolic measures.精神分裂症后抑郁的药物治疗研究的性别分析(STOP-PD):性别和年龄作为预测反应的指标,以及与治疗相关的体重指数和代谢指标的变化。
J Clin Psychiatry. 2013 Oct;74(10):1003-9. doi: 10.4088/JCP.13m08400.
6
Obesity in bipolar disorder: an overview.双相障碍中的肥胖:概述。
Curr Psychiatry Rep. 2012 Dec;14(6):650-8. doi: 10.1007/s11920-012-0313-8.
7
Correlates of weight gain during long-term risperidone treatment in children and adolescents.长期利培酮治疗期间儿童和青少年体重增加的相关因素。
Child Adolesc Psychiatry Ment Health. 2012 May 29;6(1):21. doi: 10.1186/1753-2000-6-21.
8
Atypical antipsychotics and the neural regulation of food intake and peripheral metabolism.非典型抗精神病药物与食物摄入和外周代谢的神经调节。
Physiol Behav. 2011 Sep 26;104(4):590-8. doi: 10.1016/j.physbeh.2011.05.033. Epub 2011 Jun 12.
9
Weight gain and changes in metabolic variables following olanzapine treatment in schizophrenia and bipolar disorder.奥氮平治疗精神分裂症和双相情感障碍后体重增加和代谢变量的变化。
Clin Drug Investig. 2011;31(7):455-82. doi: 10.2165/11589060-000000000-00000.
10
Can body mass index help predict outcome in patients with bipolar disorder?体重指数能否帮助预测双相情感障碍患者的预后?
Bipolar Disord. 2009 Sep;11(6):650-6. doi: 10.1111/j.1399-5618.2009.00730.x.